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Abstract
Background:  Nicotine may aid reaction time, learning and memory, but smoking increases
cardiovascular risk. Cardiovascular risk factors have been linked to increased risk of dementia. A
previous meta-analysis found that current smokers were at higher risk of subsequent dementia,
Alzheimer's disease, vascular dementia and cognitive decline.
Methods: In order to update and examine this further a systematic review and meta-analysis was
carried out using different search and inclusion criteria, database selection and more recent
publications. Both reviews were restricted to those aged 65 and over.
Results: The review reported here found a significantly increased risk of Alzheimer's disease with
current smoking and a likely but not significantly increased risk of vascular dementia, dementia
unspecified and cognitive decline. Neither review found clear relationships with former smoking.
Conclusion: Current smoking increases risk of Alzheimer's disease and may increase risk of other
dementias. This reinforces need for smoking cessation, particularly aged 65 and over. Nicotine
alone needs further investigation.
Background
That smoking has a negative impact on health is no longer
queried. In addition to the well known risks of lung can-
cer, smoking is also an independent predictor of cardio-
vascular morbidity, mortality and development of
myocardial infarction [1]. Smoking may also accelerate
cerebral atrophy, perfusional decline and white matter
lesions [2]. In contrast, nicotine has plausible mecha-
nisms for aiding cognitive function. Throughout the
cholinergic system there are nicotinic acetylcholine recep-
tors which can bind to nicotine. Use of nicotine as an ago-
nist is said to up regulate these receptors in a dose
dependent fashion, possibly by several hundred percent,
depending on brain region [3,4]. The use of nicotine has
also been found to aid attention, reaction time and some
learning and memory [4]. Although this effect may be
short lived if exposure is discontinued, potential benefits
may be conferred as such receptors are thought to decline
with ageing, with Alzheimer's disease and Lewy Body
dementia [4]. A histopathological study in this area found
mixed results with a possible protective effect of smoking
against senile plaque formation in twenty eight matched
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pairs, and a positive correlation between the amount of
smoking and neurofibrilliary change, but in smokers only
[5].
A Cochrane review attempted to investigate the use of nic-
otine in Alzheimer's disease, but found no suitable data
[6]. Other authors have compared smokers and non
smokers in case control studies of Alzheimer's disease or
cross sectional population studies and found mixed
results. For example, studies have found no difference
between smokers and non smokers in white or African
American populations [7]; significantly increased risk of
current smoking (OR2.33) in a Chinese population [8]
and a reduced risk in male smokers only, (but in an
unmatched case control study) [9]. Still further studies
found male and female differences [10], an association
between current smoking and reduced psychomotor
speed, cognitive flexibility [11] and no difference between
smokers and non smokers aged over fifty years for mem-
ory, reasoning and simple choice reaction time [5,12]. The
smokers however, did die earlier.
One of the difficulties with research in this area is the
potential overlapping of risk and protective factors as well
as the undoubtedly negative constituents in cigarette
smoke, despite smoking remaining the primary means by
which people gain nicotine. Other issues include the clus-
tering of risk or protective factors, the possible cognitive
protection from a healthy diet [13], the influence of drink-
ing alcohol and obesity. One study found that smoking
was associated with reduced risk of Alzheimer's disease in
drinkers only [14,15], and in seventy year olds both
smoking and obesity were associated with poorer cogni-
tion on a neuropsychological battery [16]. Smoking
behaviour may also change over time and by sector or
cohort within the population; for example, smoking rates
may be markedly lower with increasing age, lower in
women [17] and may be impacted upon by ill health or
change in circumstances. Studies may also vary in quality
with both matched and unmatched case control studies
and much cross sectional data in the literature. In addition
to this subjects, either non smokers or smokers, may self
select for studies [18] and survival biases may be present
with smokers dying younger [19].
As smoking may have a negative effect on the cardiovascu-
lar system, it may plausibly impact on the development of
dementias, both Alzheimer's Disease and vascular demen-
tia. Several issues combine to make the study of different
dementias and smoking important, the impact of these
dementias in society, the difficulty in identifying pure
forms of either, the increased risk of dementia and cogni-
tive decline in the elderly and the ageing population. All
of this combines to focus on the need for an increased
understanding of risk and protective factors, particularly if
these can be impacted upon via public health messages.
The most recent systematic review is wide ranging and was
published by an Australian group in June 2007. The
authors examined data from the start of the literature
databases 'Pubmed', 'Psychinfo' and 'Cochrane CENTRAL'
to June 2005 [20]. It focused on those over the age of 65
which is pertinent since the risk of dementia increases
strikingly with increasing age. This review included only
longitudinal studies and found that current smokers rela-
tive to never smokers were at increased risk of Alzheimer's
disease, Vascular dementia, any dementia and cognitive
decline. Former smokers had lower risks than current
smokers at least for Alzheimer's disease and cognitive
decline [20]. In parallel to their observations we carried
out a similar systematic review using narrower search
terms, wider inclusion criteria and more modern litera-
ture, including longitudinal studies published between
1995 and 2007 and identified using the literature data-
bases Embase, Psychinfo and Medline. Our review was
aimed to examine the relationship between smoking,
dementia and cognitive decline in an elderly population.
Method
Search terms 'smoking' and 'dementia' or 'vascular
dementia' or 'multi infarct dementia' or 'Alzheimer's dis-
ease' or 'cognitive impairment' or 'cognitive decline' were
used as keywords. The databases Medline, Embase and
Psychinfo were searched for English language publica-
tions relating to human populations and which occurred
between 1996 and November 2007. The Cochrane data-
base of reviews was also searched. This time period was
chosen as the methodology and computing power availa-
ble for research changed greatly in the early 1990s. When
available, standard search categories were also used as
matched to the above terms. All searches were limited to
the pre-defined search engine limits of subjects aged 65
and over. Two health service researchers appraised all
abstracts and selected manuscripts independently, any
discrepancies in decisions were discussed to achieve a
unanimous choice of articles. No hand searching was car-
ried out.
Studies were quality assessed by both researchers in
accordance with the guidelines presented by Stroup et al
for the reporting of meta-analyses of epidemiological
studies [21]. There were no randomised controlled trials.
Case studies, letters, consensus opinion from conferences
and expert opinions or editorials were not included. In
order to aid investigation of causality only longitudinal
studies were assessed. Where studies had multiple publi-
cations and their outcomes differed all papers were
included. When the outcomes were the same the paper
with the longest follow up was selected, in order to pre-BMC Geriatrics 2008, 8:36 http://www.biomedcentral.com/1471-2318/8/36
Page 3 of 7
(page number not for citation purposes)
vent doubly including data. Where possible, meta-analy-
ses and funnel plots were created. The most conservative
results were used from each of the constituent popula-
tions, because the different populations were heterogene-
ous and had received adjustment for different factors no
further adjustment was carried out. The definitions of cur-
rent, ex and never smokers were taken from the published
papers.
Results
50 relevant papers were selected for full text examination
from the three search engines and 28 retained [22-49] (see
additional file 1 for further details). The 28 papers
described 23 longitudinal studies. These studies were
extracted into a summary table, see additional file 2.
Those where data were reported as Odds Ratios (OR) or
Relative Risks (RR) were combined into meta-analyses.
v Five studies found a significant link between current
smoking and increased risk of incident dementia [22-28].
v Seven studies found a significant link with increased
risk of cognitive decline [29-32,43,46,49]
v Six found no significant link with dementia or cognitive
decline and current smoking [34,36,37,39,40,42]
v One found a significant link between dementia and
past or current smoking [47].
v No studies found a significant link between former
smoking and incident cognitive decline or dementia.
v Of the other studies, one found an association between
smoking and a diminished risk of decline for attention
and visuospatial tasks [44] and one, that a lack of smoking
significantly predicted maintenance of cognitive function,
OR 1.73 (95% confidence interval 1.30–2.20) [48].
Two sets of meta-analyses were carried out. The summary
ratios below are for current smokers against never or non-
smokers for the four outcomes of
v Alzheimer's disease (1.59 (95% CI 1.15–2.20))
v vascular dementia (1.35 (95% CI 0.90–2.02))
v dementia unspecified (1.16 (95% CI 0.90–1.50))
v cognitive decline (1.20 (95% CI 0.90–1.59)),
For ex smokers compared to never smokers
v Alzheimer's disease (0.99 (95% CI 0.81–1.23))
v vascular dementia (1.05 (95% CI 0.72–1.54))
v dementia unspecified (0.90 (95% CI 0.75–1.07))
v cognitive decline (0.90 (95% CI 0.74–1.10)).
Measurements of heterogeneity were not significant with
the exception of that for Alzheimer's disease with current
smoking (Cochran Q = 23.25, p = 0.0015).
Publication bias did not seem evident from funnel plots
(see additional file 3 for further details). Random effects
models were used and the summary ratios showed a sig-
nificantly increased risk of Alzheimer's disease with cur-
rent smoking. Forest plots showing the effect of current
smoking on Alzheimer's disease, Vascular dementia,
dementia and cognitive decline are included as figures 1,
2, 3, 4.
These findings have to be understood in the context of the
small numbers of results available for meta analysis for
some outcomes and methodological issues such as the
likelihood of increased mortality of smokers. Methodo-
logical issues are discussed further below.
Methodological issues
Study design
Study design varied with cohort and case control method-
ology, as did length of follow up and population; with
population ranging from less than 1000 to over 34,000
[31-34,37,39-42,44,49] and including participants from
North America, China, Australia and Europe. Follow up
Current smoking and Alzheimer's disease Figure 1
Current smoking and Alzheimer's disease.
Summary meta-analysis plot [random effects]
0.5 1 2 5 10
combined 1.59 (1.15, 2.20)
HR AD [23] 1.51 (1.10, 2.08)
OR AD [28] 3.40 (1.44, 8.01)
RR AD [42] 0.83 (0.60, 1.16)
RR AD [24] 1.74 (1.21, 2.50)
OR AD [34] 1.10 (0.50, 2.40)
RR Probable AD [27] 2.70 (1.20, 6.30)
RR AD [45] 1.17 (0.69, 1.98)
RR AD [25] 2.72 (1.63, 5.42)
* ratio (95% confidence interval)
Smoking related       Smoking related  
to decreased risk      to increased risk BMC Geriatrics 2008, 8:36 http://www.biomedcentral.com/1471-2318/8/36
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times ranged from one [32] to 47 [42] years although the
majority were less than 10 years. More detail is provided
in table 1.
Not all studies gave a clear indication of participant age at
baseline with some reporting mean age, some minimum
age and some age range. Despite this, when taking the
available data regarding baseline age and follow up time
into account mean age at follow up seems likely to be 65
or over. The factors that were adjusted for in the reported
analyses also varied with most authors adjusting for age,
gender and education, although a handful included wider
factors such as ethnicity, income, social class, history or
current cardiovascular or respiratory diseases, blood pres-
sure and alcohol use [22-49]
Outcome
Four studies had multiple publications, the Honolulu
Asia Aging Study [30,45], the Washington Heights Medi-
care recipient's study [[26,27], and [31]], the Sydney
Older Persons study [40,41] and the Rotterdam study
[22,23]. Only those from the Sydney Older Persons study
and the Rotterdam study had the same outcomes in each
paper. The longest follow up was used in each case. Of the
two publications from the Washington Heights data set,
the cohort analysis reporting possible or probable Alzhe-
imer's disease was used in preference to the case control
analysis incorporating Alzheimer's disease. Each paper
from the Honolulu Asia Aging study reported on a differ-
ent outcome.
The majority of studies specified that prevalent dementia
was excluded at baseline or that they had assessed inci-
dent dementia or cognitive decline [22-36,39-41,44-47].
The remainder reported study designs that made prevalent
dementia at baseline highly unlikely. One study assessed
smoking behaviour in midlife so although assessment for
dementia in later life included prevalent cases these are
highly unlikely to have been present at the time of smok-
ing assessment [45]. Standardised criteria for the assess-
ment and diagnosis of dementia and cognitive decline
were used in most studies including those from the Diag-
nostic statistical Manual edition three revised (DSMIIIR)
the National Institute of Neurological and Communica-
Current smoking and vascular dementia Figure 2
Current smoking and vascular dementia.
Summary meta-analysis plot [random effects]
0.2 0.5 1 2 5
combined 1.35 (0.90, 2.02)
RR VaD or Lewy body dementia [42] 0.94 (0.49, 1.82)
RR VaD [23] 1.10 (0.43, 2.83)
RR VaD [45] 1.14 (0.60, 2.13)
RR VaD [25] 1.98 (1.53, 3.12)
* ratio (95% confidence interval)
Smoking related       Smoking related  
to decreased risk      to increased risk 
Current smoking and dementia (unspecified) Figure 3
Current smoking and dementia (unspecified).
Summary meta-analysis plot [random effects]
0.5 1 2 5
combined 1.16 (0.90, 1.50)
Dementia [42] 0.84 (0.63, 1.13)
Dementia [24] 1.39 (1.03, 1.89)
Dementia [23] 1.42 (1.07, 1.89)
Dementia [34] 1.40 (0.80, 2.70)
Dementia [35] 0.90 (0.50, 1.50)
* ratio (95% confidence interval)
Smoking related       Smoking related  
to decreased risk      to increased risk 
Current smoking and cognitive decline Figure 4
Current smoking and cognitive decline.
Smoking related       Smoking related  
to decreased risk      to increased risk BMC Geriatrics 2008, 8:36 http://www.biomedcentral.com/1471-2318/8/36
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tive Diseases and Stroke/Alzheimer's Disease and Related
Disorders Association [NINCDS-ADRDA] for the diagno-
sis of Alzheimer's disease and the Mini-Mental State Exam
(MMSE), [24,25,27,29,33,34,37,40,42,47,48]. Some
studies used more than one instrument and some
reported detailed neuropsychological testing
[38,40,42,49]. Other instruments included the Portable
Mental Status Questionnaire [39], the Clinical Dementia
Rating scale [26,27], the Organic Brain syndrome scale
[32] and the Cognitive Abilities Screening Instrument
(CASI) [30,45]. One study used solely the information
from death certificates [42].
The assessment of smoking was by self report and was also
fairly standard with most studies reporting on smokers
versus non smokers. Only cigarette use was reported in
sufficient detail. Few studies reported the characteristics of
smokers compared to non smokers but those who did
found that never smokers were older, more highly edu-
cated, drank less alcohol and may be more likely to be
female [25,29,30,34,45]. One study reported that former
and current smokers showed younger age of dementia
onset [22]. Unsurprisingly, mortality during study follow
up was also greater with smoking [25,37,39,40,43,45]
and three studies assessed causes of death from death cer-
tification data [22,34,42]. Non participation or loss to fol-
low up was associated with lower educational levels,
higher levels of impairment, age, smoking, body mass
index, cardiovascular risk (for example diabetes and
hypertension) and membership of an ethic minority
group [36,38,39,44,46]. One study reported that those
who refused to continue were not significantly different in
age or MMSE score at baseline [40], another reported that
they were older but there were no differences in tobacco
use [36]. A further paper reported that those who refused
to continue had lower MMSE and included proportion-
ally more smokers and abstainers from alcohol [37] and
another that lower income was associated with refusal but
that there were no differences in follow up for sex, age,
smoking or drinking levels [32]. Although the latter study
followed subjects only for one year [32].
Discussion
In comparison to the previous meta-analysis [20] which
found an increased risk for all outcomes with current
smoking (summary ratios and 95% confidence intervals);
Alzheimer's disease 1.79 (1.43–2.23), vascular dementia
1.78 (1.28–2.47), any dementia 1.27 (1.02–1.60), our
analyses found a significant relationship between
increased risk of Alzheimer's disease and current smoking
and summary ratios over one for vascular dementia,
dementia unspecified and cognitive decline although they
were not significant.
When we examined former smokers we found summary
ratios close to unity for all outcomes and no significant
results, as did the previously published meta-analysis
using older literature. The meta-analysis reported here
focused on the last 10 years of published literature up
until November 2007 and included the database Embase
whereas the most recently published analysis [20] omitted
Embase but included 'Cochrane CENTRAL' and reported
on older literature until June 2005. Although we chose to
include more recent literature, less and different search
terms and arguably wider inclusion criteria it is interesting
to note that our findings are broadly in support of theirs
and strengthening the conclusion that current smoking is
likely to increase risk of incident dementia particularly
Alzheimer's disease.
A note of caution should be sounded with regard to the
interpretation of the data relating to exsmokers as the
studies were not always consistent or clear with regard to
the time since stopping smoking and the level of smoking
that had previously been usual. Similar issues relate to
current smokers in terms of amount, however, this was
not consistently reported in the studies and may be biased
by the higher death rates in smokers, likely to be even
higher in heavy smokers. If pack years had been reported
consistently in the published literature, or could be avail-
able for further analysis this may allow further explora-
tion. Although only one of our meta-analyses was
significant in measures of heterogeneity there remain
methodological issues inevitably associated with combin-
ing several different studies and the flaws inherent in
those studies themselves, in addition to this resource lim-
itations did not permit hand searching and the published
literature only was used without contacting individual
authors directly or weighting individual studies. This is a
limitation and may have resulted in an under-representa-
tion of negative studies and a possible source of bias.
Despite these limitations it does seem likely that current
smoking may be a risk factor for the most common
dementia, Alzheimer's disease. It may also be a risk factor
for other dementias and cognitive decline. These findings
fit with other evidence of smoking as a risk factor for car-
diovascular and cerebrovascular disease, stroke, silent inf-
arction, increased oxidative stress, atherosclerosis and
inflammation all of which may impact negatively on cog-
nitive functioning and dementia incidence [50]. Evidence
presented here adds another reason for ceasing to smoke
or for preventing smoking from starting. The effects of nic-
otine itself may be different and at least one study found
less decline in attentional processes with smoking which
may be as would be expected from increased nicotine con-
sumption. Further studies are clearly required although
smoking is clearly not an advantageous way to test this.BMC Geriatrics 2008, 8:36 http://www.biomedcentral.com/1471-2318/8/36
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Conclusion
Despite the limitations inherent in combining multiple
studies it seems likely from the analyses presented here
that smoking increases risk of developing Alzheimer's dis-
ease and may also be a risk factor for other dementias.
Certainly it provides a further reason for preventing or
ceasing smoking.
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